Unadjusted analysis found relatively higher (4 and 5.4% additional) weight loss, HbA1c (0.4% additional) reduction, and fewer gastrointestinal side effects with tirzepatide 10 and 15 mg, respectively, than with semaglutide 2.4 mg [25]
The rates of adverse events, predominantly hypoglycemia, were lower in the standard-therapy group than in the intensive-therapy group
FDA-Approved Brand-Name Medications vs
The critical context: Lean mass loss on a GLP-1 lands in roughly the same range as lifestyle-based weight loss about 2030% of total weight lost
Compounding pharmacies are licensed under state and federal regulations, but compounded products occupy a distinct regulatory category from brand-name FDA-approved drugs
The company that makes it, Currax, has a program to help with your out-of-pocket costs